1381 related articles for article (PubMed ID: 22804960)
21. Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma.
Kampantais S; Kounatidis I; Kotoula V; Vakalopoulos I; Gkagkalidis K; Dimitriadis G
Int J Biol Markers; 2020 Dec; 35(4):80-86. PubMed ID: 33118406
[TBL] [Abstract][Full Text] [Related]
22. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
[TBL] [Abstract][Full Text] [Related]
24. Role of the intracellular localization of HIF-prolyl hydroxylases.
Yasumoto K; Kowata Y; Yoshida A; Torii S; Sogawa K
Biochim Biophys Acta; 2009 May; 1793(5):792-7. PubMed ID: 19339211
[TBL] [Abstract][Full Text] [Related]
25. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
[TBL] [Abstract][Full Text] [Related]
26. Rhapontigenin inhibited hypoxia inducible factor 1 alpha accumulation and angiogenesis in hypoxic PC-3 prostate cancer cells.
Jung DB; Lee HJ; Jeong SJ; Lee HJ; Lee EO; Kim YC; Ahn KS; Chen CY; Kim SH
Biol Pharm Bull; 2011; 34(6):850-5. PubMed ID: 21628883
[TBL] [Abstract][Full Text] [Related]
27. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
Gong K; Zhang N; Zhang K; Na Y
Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
[TBL] [Abstract][Full Text] [Related]
28. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
Wolf C; Smith S; van Wijk SJL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
[TBL] [Abstract][Full Text] [Related]
29. iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation.
Zhao D; Zheng S; Wang X; Liu H; Zhao K; Li L; Hu Y
Oncogene; 2022 Mar; 41(13):1944-1958. PubMed ID: 35169254
[TBL] [Abstract][Full Text] [Related]
30. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high
Miikkulainen P; Högel H; Seyednasrollah F; Rantanen K; Elo LL; Jaakkola PM
J Biol Chem; 2019 Mar; 294(10):3760-3771. PubMed ID: 30617181
[TBL] [Abstract][Full Text] [Related]
32. [Activation of HIF-1α/ACLY signaling axis promotes progression of clear cell renal cell carcinoma with VHL inactivation mutation].
Ma Y; Wang YH; Huang S; Zou ZG; Hu L; Guo LC
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1230-1236. PubMed ID: 38058039
[No Abstract] [Full Text] [Related]
33. Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein.
Song X; Yao J; Wang F; Zhou M; Zhou Y; Wang H; Wei L; Zhao L; Li Z; Lu N; Guo Q
Toxicol Appl Pharmacol; 2013 Sep; 271(2):144-55. PubMed ID: 23707765
[TBL] [Abstract][Full Text] [Related]
34. Constitutive expression of HIF-α plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma.
Tóth K; Chintala S; Rustum YM
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):642-7. PubMed ID: 25046225
[TBL] [Abstract][Full Text] [Related]
35. Src activates HIF-1α not through direct phosphorylation of HIF-1α specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway.
Lee HY; Lee T; Lee N; Yang EG; Lee C; Lee J; Moon EY; Ha J; Park H
Carcinogenesis; 2011 May; 32(5):703-12. PubMed ID: 21335603
[TBL] [Abstract][Full Text] [Related]
36. TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells.
Han WQ; Zhu Q; Hu J; Li PL; Zhang F; Li N
Biochim Biophys Acta; 2013 Jun; 1833(6):1454-62. PubMed ID: 23466866
[TBL] [Abstract][Full Text] [Related]
38. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
39. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
[TBL] [Abstract][Full Text] [Related]
40. von Hippel-Lindau β-domain-luciferase fusion protein as a bioluminescent hydroxyproline sensor for a hypoxia-inducible factor prolyl hydroxylase assay.
Hong S; Yum S; Ha NC; Jung Y
Anal Biochem; 2010 Dec; 407(2):220-5. PubMed ID: 20705044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
